This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)
1403-0001
Phase 1 other active
Quick answer
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors) for Advanced or metastatic solid tumors is a Phase 1 program (other) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Advanced or metastatic solid tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active